Lupin Of India Licenses Aussie NeoClone's Cancer Protein Technology
This article was originally published in PharmAsia News
Executive Summary
India's Lupin has signed a licensing agreement with Australia's NeuClone to in-license Lupin's recombinant protein technology for use in cancer research